During the quarter, the company received approval for the world’s first plasmid DNA vaccine for COVID-19, ZyCoV-D.

Zydus Cadila, EBIDTA, Human Health Formulations Business, Plasmid DNA Vaccine, COVID-19, ZyCoV-DThe company’s business in India which includes the human formulations and consumer health business contributed 43% of consolidated revenue during the quarter and saw 12% year-over-year growth.

Zydus Cadila recorded business growth of 12% in Human Health Formulas with consolidated revenue of Rs. 3,785 crores, up 3% YoY (YoY) for the second quarter ended 30th September 2021. EBIDTA for the quarter was Rs. 861 crores, an increase of 6% year-on-year.

The company’s business in India which includes the human formulations and consumer health business contributed 43% of the consolidated revenue during the quarter and saw a growth of 12% YoY, reporting sales of Rs.1591 crore during the quarter. The human health formulations business grew 12% and the consumer health business grew 13% during the quarter.

EBIDTA margin for the quarter was 22.7%, an improvement of 50 basis points year over year. Profit after tax (PAT) when adjusted for exceptional items and one-time gains at the expense of selling animal health-based market pledges. 597 crore, up 6% year-on-year.

“During the quarter, the company received approval for the world’s first plasmid DNA vaccine for COVID-19, ZyCoV-D. Furthermore, the company also received approval from DCGI to conduct Phase III trials of a two-dose regimen of the vaccine. Results from Phase 1 clinical trials have been published. for ZyCoV-D in the journal E-Clinical Medicine of Lancet,” according to the company’s release.

Excluding institutional sales of COVID products, human health formulations business growth was 17%. The company’s business in the United States recorded sales of Rs. 1,498 crore, up 3% on a sequential basis. The company launched Enoxaparin Sodium Injection in the United States during the quarter. This is the first public launch of the product by an Indian player.

With advances in lead molecule Saroglitazar Mg, the company recently randomized the first patient to a Phase 2(b) prospective, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of Saroglitazar Magnesium in subjects with nonalcoholic steatohepatitis. (NASH) and fibrosis.

Positive results from a Phase II(A) global clinical trial evaluating Saroglitazar Magnesium in patients with NASH were published in October 2021 in an issue of the peer-reviewed medical journal of international repute ‘Hepatology’.

In its quest to provide solutions for rare diseases, Sentynl Therapeutics, Inc. , a wholly owned subsidiary of the company along with Cyprium Therapeutics, Inc. , a partner company of Fortress Biotech, Inc. Positive results from efficacy and safety analysis Data from two completed pivotal studies in patients with Menkes disease treated with CUTX-101, copper histides (CuHis) were combined. The study data will be presented as a virtual poster at the 2021 American Academy of Pediatrics National Conference and Exhibition.

Get live stock quotes from BSE, NSE, US market and latest NAV, mutual fund portfolio, see the latest underwriting news, best IPOs, calculate your tax with income tax calculator, see top market gainers, biggest losers and best stock funds. like us Facebook social networking site and follow us Twitter.

Source link

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *